About Us

Glen Research, part of Maravai LifeSciences, is a leading provider of reagents for DNA and RNA oligonucleotide synthesis, labeling, and modification. Known for its proprietary Sterling™ line of reagents marked with its Sterling Seal of Quality Assurance, Glen analyzes and certifies these reagents for purity and performance ensuring consistent, dependable and reliable results. Glen also specializes in oligonucleotide purification supplies under the Glen-Pak™ and Glen Gel-Pak™ product lines.

Glen supplies its reagents to: researchers investigating diverse genetic diseases and disorders; businesses and organizations developing new genetic therapies; and, biopharmaceutical, diagnostic and life science OEM partners who incorporate Glen Research offerings into their own products.

Glen takes pride in delivering operational excellence, experienced technical support and superior customer service and is ISO 9001:2015 certified. As part of its Quality Management System, Glen verifies that its operations and processes meet all management criteria for consistency and performance.

Glen was founded in 1987 by Hugh and Margaret Mackie with a mission to provide state-of-the art reagents to researchers. In 1993, Glen introduced the Sterling line of products, a new standard of accomplishment for oligonucleotide synthesis.

Glen Research Facility

30 Years of Assured Quality for Oligo Synthesis

1987

Glen Research was incorporated in the Commonwealth of Virginia

1991

Company awarded SBIR grant for the investigation of large scale oligonucleotide synthesis using H-phosphonate chemistry

1993

Glen Research introduced the Sterling line of products, a new standard of accomplishment for oligonucleotide synthesis

1995

Glen Research negotiated an exclusive agreement to supply 5’-biotin phosphoramidite worldwide

1996

Company negotiated an exclusive license with Gilead Sciences to supply C5-propynyl pyrimidine nucleosides and G-Clamp phosphoramidites

1997

Glen Research moves into a custom built building in Sterling, Virginia

1999

Company awarded patents for a chemical phosphorylation reagent compatible with DMT-ON purification

2002

Company made an agreement with Epoch Biosciences, Inc. to supply their proprietary dyes and nucleosides to the research market

2003

Glen Research negotiated an agreement with GE Healthcare Biosciences Corp. to supply Cyanine Dyes to the research market

2004

Company awarded patents for a truly universal support for oligonucleotide synthesis - US III.

2006

In collaboration with Berry & Associates, Glen Research awarded patents for pyrrolo-C analogues, fluorescent C analogues

2008

Glen Research obtained a license for the sale of Glen UnySupport from Ionis Pharmaceuticals

2013

In collaboration with Nelson Biotechnologies, Inc., company awarded patent for serinol phosphoramidites and supports

2017

Glen Research is acquired by Maravai LifeSciences

2019

Glen Research received its ISO 9001:2015 certification for Quality Management Systems

Company Information

Year Founded:
1987
Number of Employees:
30+
Facilities:
Headquarters, Sterling, VA USA
Key Personnel:
Christine Dolan, Chief Operating Officer
Christine was appointed COO for Glen Research in October 2018. She is accountable for all operations including designing/implementing business processes and organizational structures/strategies to ensure continued longevity and growth. She also leads the Operations for Cygnus Technologies LLC, under the Maravai portfolio. Prior to joining Maravai, she was the SVP of Product Development at Catalent Pharma Solutions and served in several senior global Quality, Operations and Business Unit leadership roles during her 8 year tenure. In addition, she has held progressive operational management roles at GE Healthcare and Amersham Health. Christine started her career as a microbiologist, and holds a B.S. in Biology from Lenoir Rhyne College.

David Weber, VP and Chief Commercial Officer
David comes to Maravai LifeSciences with over 35 years of experience in life sciences industry commercial leadership and general management. David is responsible for all marketing, sales, product development, commercial strategy, service and support for all Maravai LifeSciences portfolio companies. Prior to joining Maravai LifeSciences, David served as Executive Vice President and Chief Commercial Officer for Affymetrix leading up to its acquisition by Thermo Fisher Scientific. Earlier in his career, David held a variety of commercial leadership roles in life science companies including Amersham Biosciences (GE Healthcare), Eksigent Technologies, Cyntellect, Stratagene and The Linus Group.

Harjit Kullar, VP, Marketing
Harjit comes to Maravai LifeSciences with over 15 years of experience in sales and marketing in the life sciences and diagnostics industries, most recently holding the position of Vice President of Marketing at Transgenomic. Earlier in his career, Harjit held a variety of commercial leadership roles in life science companies including Bio-Rad Laboratories, Thermo Fisher Scientific, Life Technologies, LifeSpan BioSciences and Abcam. Harjit received a BSc in Biochemistry & Pharmacology from University of Southampton, a Ph.D. in Cancer Biology from University of Birmingham and an MBA from University of Cambridge.
Contacts for the Media:
David Weber, Chief Commercial Officer
Maravai LifeSciences
(650) 697-3600
[email protected]